Source comparison
Using MK-677 for Sleep Improvement Research Evidence: Comparison
MK-677 (Ibutamoren) Ghrelin receptor agonist → pulsatile GH release +50% Stage 4 sleep, +20% REM (JCEM 1997) No tolerance observed in 12-month trials Research compound, not FDA-approved for human use Strongest evidence for deep sleep enhancement without recept
This comparison does not assign a generated winner or score.
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist → pulsatile GH release
- +50% Stage 4 sleep, +20% REM (JCEM 1997)
- No tolerance observed in 12-month trials
- Research compound, not FDA-approved for human use
- Strongest evidence for deep sleep enhancement without receptor desensitization
- Exogenous GH Injection
- Direct GH replacement
- Increases slow-wave sleep initially, suppresses endogenous GH over time
- Negative feedback reduces natural production
- Prescription-only, Schedule III
- Effective acutely but disrupts physiological pulsatility
- Melatonin
- Circadian phase-shift via MT1/MT2 receptors
- Reduces sleep onset latency, minimal effect on sleep architecture
- Receptor desensitization with chronic use
- OTC supplement
- Helps timing but does not deepen sleep stages
- Benzodiazepines (e.g., Temazepam)
- GABA-A receptor agonist
- Suppresses Stage 4 and REM, increases Stage 2
- Rapid tolerance (2–4 weeks)
- Prescription, controlled substance
- Sedates but degrades restorative sleep quality
- Cognitive Behavioral Therapy for Insomnia (CBT-I)
- Behavioral sleep restriction + stimulus control
- Increases sleep efficiency and slow-wave sleep percentage over 6–8 weeks
- No physiological tolerance
- Non-pharmacological intervention
- Gold standard for chronic insomnia, no pharmacological side effects
- MK-677 is not FDA-approved for human therapeutic use. All published research involves investigational protocols. Compounds like MK 677 are available as research-grade materials for laboratory investigation, not as prescription sleep aids.